SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant volatility following an announcement of a massive equity offering intended to finance a substantial backlog of AI-related orders. The community remains deeply divided, with some investors viewing the dilution as a necessary step to scale production for rapid growth, while many others are sounding alarms over the company's financial health, management's history of controversy, and the potential for further share price suppression.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing significant downward pressure as investors react negatively to the company's planned $40 billion financing and massive capital expenditure surge, despite a strong earnings beat and record-breaking revenue backlog. While long-term bulls remain optimistic about Oracle's AI infrastructure demand and backlog growth, the community is currently debating whether this is a temporary volatility event or a sustained structural concern over dilution and debt leverage.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently experiencing significant market volatility as investors recalibrate their positions ahead of the high-profile SpaceX IPO. While the community remains deeply divided between long-term believers in Rocket Lab's launch execution and skeptics who are rotating capital into the larger industry debut, discourse is heavily focused on whether current pullbacks represent a strategic buying opportunity or a broader sector-wide valuation correction.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is experiencing intense volatility driven by conflicting signals surrounding U.S.-Iran military tensions, with traders weighing claims of imminent peace deals against reports of ongoing strikes. Community sentiment is deeply polarized, as investors navigate broader concerns over inflation and the upcoming SpaceX IPO while debating whether current market movements are a genuine recovery or a temporary liquidity trap.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The SMCX ETF is experiencing intense community focus following a sharp, high-volume price decline triggered by an investigation into alleged export violations and chip diversion to China involving Super Micro Computer executives. While some investors are viewing the volatility as a potential bottom-fishing opportunity and speculating on a short squeeze, many in the community are warning about the inherent risks of leveraged decay, the potential for further reverse splits, and the uncertainty surrounding the underlying company's legal and compliance troubles.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is facing intense market scrutiny as investors react to escalating geopolitical tensions in the Middle East and a contentious economic climate. Community members are actively debating the company's financial future while expressing significant polarization over executive commentary regarding inflation and ongoing military conflicts.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is experiencing a sharp pullback following an earnings report that showed wider-than-expected losses, despite ongoing community enthusiasm for the stock's long-term potential as a U.S.-based uranium producer. Investors are actively debating whether to accumulate shares during this volatility to capitalize on the secular bull case for nuclear energy and domestic fuel independence, or to remain on the sidelines due to current operational costs.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is facing intense scrutiny from investors who are deeply divided over the company's aggressive pivot into the alcohol sector and ongoing share dilution. While some maintain hope for growth tied to upcoming federal regulatory hearings and international medical expansion, the community is vocally calling for leadership changes, frequently citing frustration with the stock's persistent downward trend compared to US-based competitors.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing heightened activity as investors weigh upcoming Q3 clinical data catalysts against the backdrop of an intensely competitive obesity drug sector. The community remains focused on potential partnership or buyout prospects, with active discussions debating management's strategic communication and the stock's performance relative to broader market momentum.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending as investors debate a recent report regarding potential strategic partnerships and M&A activity, with the community closely tracking management's comments on the company's future. While some remain bullish on the long-term potential for a buyout, others are focused on upcoming clinical catalysts and remain skeptical about the timing of any formal transaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation PR Newswire RALEIGH, N.C. and...

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 RALEIGH, N.C.and TEL-AVIV, Israel, June 8...

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense...

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease RedHill's RHB-204 Demonstrates Comparable MAP Killing...

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights PR Newswire TEL AVIV...

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity...

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036)  DelveInsight

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight H. pylori Infections Market in the 6MM to Observe...

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034)  DelveInsight

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...

Joint U.S. Commercialization of RedHill's Talicia Commences

Joint U.S. Commercialization of RedHill's Talicia Commences Joint U.S. Commercialization of RedHill's Talicia Commences PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, Feb. 25, 2026 The full sales...

What's Going On With Redhill Biopharma Stock On Tuesday?

RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.read more...

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

RDHLRedHill Biopharma Ltd.

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest RDHL News